Abstract

Introduction

Short telomeres have been associated with adverse lifestyle factors, cardiovascular risk factors and age-related diseases, including cardiovascular disease (CVD), myocardial infarction, atherosclerosis, hypertension, diabetes, and also with mortality. However, previous studies report conflicting results.

Objectives

The aim of the present study has been to investigate the involvement of telomere length in all-cause and CVD mortality in subjects hospitalized for diagnostic coronary angiography of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Methods

Relative telomere length (RTL) was measured with a Q-PCR based method in 3,316 participants of the LURIC study. Age-corrected RTL was calculated as the ratio between RTL and age. Median follow-up was 9.9 years. Cox regression and Kaplan-Maier analyses were performed to evaluate the role of RTL for all-cause and cardiovascular mortality.

Results

RTL correlated negatively with age (r = -0.09; p < 0.001). In surviving patients the correlation between age and RTL was statistically significant (r = -0.088; p < 0.001), but not in patients who died during follow-up (r = -0.043; p = 0.20). Patients in quartiles 2–4 of RTL had a lower hazard ratio for all-cause mortality (HR: 0.822; 95%CI 0.712–0.915; p = 0.008) and CVD-mortality (HR: 0.836; 95%CI 0.722–0.969; p = 0.017) when compared to those in the 1st quartile. Adjustment for major cardiovascular risk factors did not change this result, however additional adjustment for age attenuated this effect. Patients in the 4th quartile of age-
Introduction

Aging is a major risk factor for the development of many common diseases, including cardiovascular disease (CVD), myocardial infarction (MI), stroke, hypertension, type 2 diabetes mellitus (T2DM), cancer, and chronic kidney disease (CKD) [1]. The prevalence of these diseases significantly increases with age, and they are major causes of frailty and death [1]. Telomeres are protective end caps of chromosomes, supporting genomic integrity and stability, key aspects of aging [1]. They are nucleoprotein structures composed by a non-coding, repetitive DNA sequence (TTAGGG) and associated proteins that form the shelterin complex [1]. Due to the inability of the DNA polymerase to fully replicate the 3' end of chromosomes, telomeres progressively shorten with every cell division [1]. The consequence of this phenomenon is that a somatic cell can undergo a defined number of doublings before telomeres become critically short, lose their protective properties and send cells into senescence, or cause cell death [1]. Therefore, mean telomere length has been used as a biomarker of biological age [1]. Short telomeres have been associated with older age, adverse lifestyle factors, such as stress, smoking and obesity and reduced physical activity [1]. In addition, telomere length has been studied as a potential biomarker of age-related diseases, such as CVD [1,2–4], MI [1,2], atherosclerosis [1], hypertension [1,5], T2DM [1], and mortality [6–8]. In population-based prospective studies it has repeatedly been shown that individuals with short telomeres have an increased risk for cardiovascular events, stroke, MI and all-cause mortality [2,3,9,10]. Despite the increase in all-cause mortality, in the general elderly population short telomeres are not necessarily associated with a higher risk of cardiovascular death [6,9]. In studies that found a significant increase in cardiovascular mortality the effect was rather small [11] or limited to distinct sub-groups, such as African-American [10].

Large prospective studies that analyzed the relationship between telomere length and mortality in high-risk populations with pre-existing cardiovascular disease are missing. The present study aimed to fill this gap of knowledge investigating the association between leukocyte telomere length and all-cause as well as cardiovascular mortality in the participants hospitalized for diagnostic coronary angiography of the prospective Ludwigshafen Risk and Cardiovascular Health (LURIC) study. The LURIC study was designed to prospectively evaluate the effect of clinical and biochemical factors on cardiovascular outcomes.

Methods

Study cohort

A detailed description of the LURIC study has been published previously [12]. Briefly, 3,316 white patients hospitalized for elective diagnostic coronary angiography at the Heart Center...
Ludwigshafen (Germany) were enrolled between June 1997 and January 2000. Inclusion criteria were: German ancestry, clinical stability except for acute coronary syndromes and the availability of a coronary angiogram. Exclusion criteria were: any acute illness other than acute coronary syndromes, any chronic disease where non-cardiac disease predominated and a history of malignancies within the past five years.

All patients underwent a physical examination, coronary angiography and electrocardiography [12]. Coronary artery disease (CAD) was defined as a visible luminal narrowing of ≥20% stenosis in ≥1 of the 15 coronary segments [12]. The diagnosis of MI was either based on electrocardiographic criteria for ST elevation or non-ST elevation combined with chest pain for >20 minutes (being refractory to sublingual nitrates and/or typical enzyme elevations) or based on a report of a diagnosis of MI in a medical document [12]. T2DM was diagnosed according to the 2014 criteria of the American Diabetes Association. Moreover, patients with a history of diabetes and those using oral anti-diabetics or insulin were considered diabetic [12].

The study was approved by the ethics committee of the Physicians Chamber of Rheinland-Pfalz and performed in accordance with the declaration of Helsinki [12]. All participants gave written informed consent [12].

Follow-up
Information about survival was obtained from local person registries. Two physicians blinded to baseline characteristics of the study participants classified causes of death by reviewing hospital records and death certificates. In the case of disagreement about classification, the final decision was made by one of the principal investigators of LURIC after appropriate review of the data [12]. Cardiovascular mortality was defined as death due to fatal MI, sudden cardiac death, death after cardiovascular intervention, stroke and other causes of death due to cardiovascular diseases [12]. The median follow-up time was 9.9 years (8.5–10.7).

Laboratory measurements
Blood samples were collected in vacutainer tubes containing an anticoagulant (EDTA (ethylenediaminetetraacetate), citrate, or lithium heparin) or in tubes without anticoagulant. Laboratory measurements were assessed using standardized routine methods as described previously [12].

Analysis of relative telomere length (RTL)
RTL was measured in genomic DNA using a quantitative-polymerase chain reaction (Q-PCR)-based assay [13]. Genomic DNA was extracted from whole blood by a standard salting-out procedure [12]. DNA quantity and quality was assessed by spectrophotometry analyzing absorbances at 230, 260 and 280 nm.

The master mix for each 20 μl PCR reaction was prepared with 4 μl LightCycler Fast Start DNA Master Plus SYBR Green I (Roche Diagnostics, Mannheim, Germany), 150 nmol/L of telomere-specific primers (TELO For, CCGTTTTTGGTTGGTTGGTTGGTTGGTTGGTTGGTT and TELO Rev, GGCTTGCCTTACCCTACCCTACCCTACCCTACCCT), or 100 nmol/L of a single-copy housekeeping gene primers (36B4 For, CAGCAAGGGAAGGTAATCC and 36B4 Rev, CCCATTCTATCATCAGCGGTACAA). In each run 40 ng of sample DNA was analyzed in duplicate, a coefficient of variation (CV) between replicates of 2.5% was considered acceptable and the average of both replicates was calculated. All samples were run in duplicate and when the CV between the replicates was more than 2.5%, the measurement-replicates were repeated.
The thermal cycling profile for both reactions consisted of a 95°C activation step, followed by 40 cycles of 95°C for 15 seconds and 58°C for 60 seconds. All Real-Time PCR reactions were carried out on a Lightcycler Instrument (Roche Diagnostics, Mannheim, Germany). A seven-point standard curve (dilution from 5 ng—100 ng) was run using a pool of 10 control DNAs for both the telomere and 36b4 PCRs to ensure linearity of the reaction ($R^2 > 0.99$). PCR efficiencies for telomeric sequence and reference gene were approximately equal, 2.1 and 1.94 respectively. The pooled control DNA was tested in all assays to allow comparability of the results. The CV between runs of the pooled control DNA was of 3.1% for the telomeric sequence and of 1.2% for the reference gene. DNA isolated from human embryonic kidney (HEK 293, Gibco, Karlsruhe, Germany) cells was used as reference control. The PCR data was analyzed with the comparative cycle threshold (Ct) method ($2^{-\Delta\Delta Ct}$) [13]. Briefly, after calibration, the Ct of the telomeric sequence was subtracted by the Ct of the reference gene to calculate ΔCt. The ΔCt of the sample was subtracted from the ΔCt of the reference control to calculate the ΔΔCt. Finally, the relative telomere length (RTL) was calculated using the $2^{-\Delta\Delta Ct}$ equation. This method measures the relative expression of the telomeric sequence (telomere, T) in comparison to a reference gene (36b4, S). RTL analysis was performed at the Department of Clinical Chemistry and Laboratory Medicine at the University Hospital of the Saarland University in Homburg/Saar.

In order to consider the age dependent decline of telomere length we also performed an age-correction of RTL by calculating the RTL / age ratio.

**Statistical analyses**

All data were examined for normality of their frequency distribution using the Kolmogrov-Smirnov test. Where indicated non-normally distributed variables were log-transformed prior to further statistical testing. Descriptive statistics provide means ($\pm$SD) or medians (10th-90th percentiles) for normally and non-normally distributed variables, respectively. Where indicated, quartiles of the entire study cohort were calculated. One-way ANOVA or a Kruskal-Wallis test were used to identify significant differences between multiple groups of continuous variables. The Mann-Whitney-U test was used to compare continuous variables between two independent groups. The correlation between RTL and age was calculated using the Pearson method. The Cox proportional hazard model was used to examine the association between quartiles of RTL and age-corrected RTL and time to death from any cause and from cardiovascular diseases. Adjustment for covariates was performed as indicated. Kaplan-Meier curves were produced to evaluate the cumulative survival during follow-up, according to quartiles of RTL and age-corrected RTL.

For the graphical presentation of results, box plots were used where the lines of each box represent the median, and the 25th and the 75th percentiles. All tests used were 2-sided and p values <0.05 were considered to be statistically significant.

All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences, version 19.0) and R v3.4.1 (http://www.r-project.org). Hazard ratio plots were drawn using the R-package ‘rms’ (v5.1–1).

**Results**

**RTL and baseline characteristics**

In the LURIC cohort median RTL was 1.7881 (0.4651–4.9341). Table 1 and S1 Table show the baseline characteristics according to RTL and age-corrected RTL quartiles, respectively.

RTL correlated negatively with age ($r = -0.09; p \leq 0.001; $ Fig 1A). Subjects below 40 years (median RTL 2.626) showed markedly longer telomeres compared to older subjects.
The median RTL was 1.9424 in individuals aged 41–60 years, 1.6953 in individuals aged 61–80 years, and 1.7451 in subjects older than 81 years (Fig 1B).

RTL correlated negatively with SBP ($r = -0.06$; $p = 0.001$) and DBP ($r = -0.039$; $p = 0.033$), but neither with BMI ($r = -0.007$; $p = 0.716$), nor with the mean heart rate ($r = -0.026$; $p = 0.16$).

**RTL and mortality**

Mean RTL was shorter in patients who died during follow up, compared to those alive (2.0405 vs. 2.2050; $p = 0.015$). Similar results were obtained using age-corrected RTL (mean age-corrected RTL 0.0426 vs. 0.0336; $p < 0.001$). Two thousand three hundred twenty one patients survived and 995 died during follow-up.

**Table 1. Baseline characteristics according to RTL quartiles.**

| Parameter          | All subjects | 1st <0.8915 | 2nd 0.8916–1.7881 | 3rd 1.7882–3.1088 | 4th >3.1089 | p-value of the trend | p-value 1st vs all others |
|--------------------|--------------|-------------|-------------------|-------------------|------------|----------------------|--------------------------|
| Age                | 62.7 ± 10.6  | 64.1 ± 9.9  | 62.6 ± 10.3       | 62.7 ± 10.8       | 61.8 ± 11.5| $<0.001$             | $<0.001$                 |
| No smoker (%)      | 36           | 36          | 34                | 36                | 37         |                      |                          |
| Ex smoker (%)      | 41           | 43          | 43                | 41                | 38         | 0.271                |                          |
| Active smoker (%)  | 23           | 22          | 23                | 23                | 25         |                      |                          |
| BMI (kg/m²)        | 27.1(22.9–32.72) | 27.0(22.7–33.0) | 27.1(22.9–33.2) | 27.1(23.1–33.2) | 27.0(22.6–32.1) | 0.769                | 0.942                    |
| SBP (mmHg)         | 140(111–173) | 142(114–177) | 140(112–171)      | 140(110–173)      | 140(110–172) | 0.054                | 0.006                    |
| DBP (mmHg)         | 81(66–96)    | 82(67–97)   | 80(67–95)         | 80(65–96)         | 81(66–96)  | 0.114                | 0.016                    |
| MHR (bpm)          | 67(55–84)    | 68(56–85)   | 68(56–83)         | 67(54–85)         | 67(54–84)  | 0.636                | 0.434                    |
| WBC (10³/nL)       | 6.76(4.80–9.80) | 6.77(4.92–9.67) | 6.81(4.91–9.90) | 6.70(4.66–9.80) | 6.70(4.73–9.80) | 0.682                | 0.892                    |
| Hb (g/dL)          | 13.9(11.9–15.6) | 13.8(11.7–15.6) | 13.9(12.0–15.8) | 13.8(11.9–15.6) | 13.9(11.9–15.7) | 0.310                | 0.278                    |
| Glucose (mg/dL)    | 102(88–154)  | 102(87–162) | 103(88–153)       | 103(88–153)       | 101(87–146) | 0.056                | 0.917                    |
| Hba1C (%)          | 6(5.2–7.9)   | 6(5.2–8.1)  | 6(5.3–7.9)        | 6(5.2–7.9)        | 5.9(5.2–7.5) | $0.012$              | 0.290                    |
| Creatinine (mg/dL) | 0.9(0.7–1.2) | 0.9(0.7–1.2) | 0.9(0.7–1.2)      | 0.9(0.7–1.2)      | 0.9(0.7–1.2) | 0.272                | 0.981                    |
| LDL (mg/dL)        | 114(75–159)  | 116(75–156) | 117(78–160)       | 111(72–158)       | 112(77–158) | 0.130                | 0.452                    |
| HDL (mg/dL)        | 37(26–53)    | 38(26–53)   | 37(27–54)         | 36(26–51)         | 38(26–53)  | $0.007$              | 0.341                    |
| TnThs (pg/ml)      | 11(1.5–113)  | 11(1.5–180) | 11(1.5–139)       | 10.5(1.5–109)     | 10(1.5–80) | 0.082                | $0.028$                  |
| NTproBNP (pg/ml)   | 293(46–2267) | 319(53–2421) | 283(47–2074)      | 285(46–2261)      | 296(38–2372) | 0.122                | $0.027$                  |

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MHR: mean heart rate; bpm: beats per minute; WBC: white blood cells; Hb: hemoglobin; Hba1c: glycosylated hemoglobin; LDL: low density lipoprotein; HDL: high density lipoprotein; TrnThs: high sensitivity cardiac troponin T; NTproBNP: pro-B-type natriuretic peptide

The median RTL was 1.9424 in individuals aged 41–60 years, 1.6953 in individuals aged 61–80 years, and 1.7451 in subjects older than 81 years (Fig 1B).

RTL correlated negatively with SBP ($r = -0.06$; $p = 0.001$) and DBP ($r = -0.039$; $p = 0.033$), but neither with BMI ($r = -0.007$; $p = 0.716$), nor with the mean heart rate ($r = -0.026$; $p = 0.16$).

**RTL and mortality**

Mean RTL was shorter in patients who died during follow up, compared to those alive (2.0405 vs. 2.2050; $p = 0.015$). Similar results were obtained using age-corrected RTL (mean age-corrected RTL 0.0426 vs. 0.0336; $p < 0.001$). Two thousand three hundred twenty one patients survived and 995 died during follow-up.

Fig 2 shows log RTL plotted with age in patients who died or survived during follow-up. In surviving patients the correlation between age and RTL was statistically significant ($r = -0.088$; $p < 0.001$), but not in patients who died during follow-up ($r = -0.043$; $p = 0.20$).

Fig 3 shows the cumulative survival rates according to quartiles of RTL. Patients in the 1st quartile were characterized by lower survival compared to those in the other quartiles ($p = 0.043$, Fig 3A) or all others combined ($p = 0.008$, Fig 3B). Similar results were obtained using age-corrected RTL quartiles (S1 Fig).

The Cox regression for all-cause and CVD-mortality according to RTL quartiles shows that RTL is a predictor for CVD and all-cause mortality in the crude model as well as in the model adjusted for major cardiovascular risk factors, such as sex, LDL cholesterol, HDL cholesterol, triglycerides, body mass index, lipid lowering therapy, blood pressure, diabetes mellitus, smoking, CAD, high-sensitive C-reactive protein and estimated glomerular filtration rate (Table 2).
However, further adjustment for age attenuated this result significantly. Furthermore, the Cox regression for all-cause and CVD-mortality according to age-corrected RTL quartiles (S2 Table) shows that age-corrected RTL is a predictor for CVD and all-cause mortality either in the crude model or with adjustment for major cardiovascular risk factors.

The relationship between RTL and age-corrected RTL and all-cause mortality are illustrated in Fig 4 and in S2 Fig, respectively.

**RTL and prevalent diseases**

RTL was lower in patients with diabetes mellitus (p = 0.033) and CAD (p < 0.001) compared to those without these conditions: median RTL was 1.69 in diabetics and 1.85 in non-diabetic subjects. Median RTL in CAD patients was 1.73 compared to 2.03 in CAD-free subjects.

**Discussion**

This large-scale prospective study demonstrates that RTL is a predictor of all causes mortality and CVD mortality. Subjects with a RTL below the median of the cohort showed a reduced survival compared to those with RTL above the median. In addition, pre-existing diabetes mellitus or CAD were associated with shorter telomeres when compared to subjects without these conditions. However, traditional cardiovascular risk factors, in particular age, explain a substantial fraction of the association between RTL and mortality.
Unselected or population based studies

Our results add substantial information to previous studies that have shown a relationship between RTL and mortality in healthy individuals or unselected populations [2,3,9,11,14,15]. For example, in the population-based Bruneck study, subjects with the longest telomeres had the lowest risk to develop CVD, stroke, MI and vascular death during a follow-up period of 10 years [2]. In the prospective WOSCOPS study that included 1,542 men with no history of MI, individuals with the shortest telomeres (1st quartile) had a 44% higher incidence of CVD compared to individuals in the 4th quartile [3]. In other large-scale studies subjects with the shortest telomeres had a 17–66% increase in mortality risk when compared to subjects with the longest telomeres [9,12,13]. Using data from four large Danish Studies including a total of 66,618 patients, Madrid et al. calculated a HR for incident ischemic heart disease during follow-up of 1.02 (95% CI, 1.01–1.03) for every 200-bp shorter telomere length [15]. However, all these studies investigated low-risk populations with a limited number of events whereas LURIC is a cohort of medium to high-risk cardiovascular patients. This may explain differences in effect size or the absence of significant effects. For example, in the Bruneck study only 88 subjects of the 800 randomly chosen individuals experienced a CVD event upon follow-up [2]. In 2,744 random selected elderly Swedish men RTL was neither related to all-cause mortality (HR 1.05; 95% CI 0.85–1.28) nor to CVD mortality (HR: 1.08; 95%CI 0.81–1.43) [8]. Similarly, Bischoff et al., did not find an association between telomere length and survival among 812 elderly

Fig 2. RTL as a function of age according to follow-up. Surviving patients are shown as blue circles ($r = -0.088; p<0.001$), deceased patients as red triangles ($r = -0.043; p = 0.20$).

https://doi.org/10.1371/journal.pone.0198373.g002
subjects (HR: 0.97; 95%CI 0.83–1.14) from three different Danish cohorts [7]. However, the participants of these two studies were older than 75 years so that other protective factors may have overridden the potentially negative effects of short telomeres [7,8].

Selected populations

Solid evidence supports a relationship between short telomeres and an increased risk of CVD [2,16,17]. A recent meta-analysis of 22,233 CAD cases and 64,762 controls from 21 population-based European cohorts showed that one standard deviation shorter telomeres increases

Table 2. Cox regression for all-cause and CVD-mortality according to RTL quartiles.

| RTL quartiles | Model 1 | Model 2 | Model 3 |
|---------------|---------|---------|---------|
|               | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| **All-cause mortality** | | | | |
| 1st (≤0.8915) | Ref. | | Ref. | | Ref. | |
| 2nd (0.8916–0.1.7881) | 0.801 (0.668–0.962) | 0.017 | 0.814 (0.678–0.977) | 0.028 | 0.844 (0.702–1.013) | 0.069 |
| 3rd (1.7882–3.1088) | 0.873 (0.730–1.043) | 0.135 | 0.854 (0.713–1.022) | 0.085 | 0.877 (0.733–1.050) | 0.154 |
| 4th (>3.1089) | 0.794 (0.662–0.953) | 0.013 | 0.861 (0.717–1.034) | 0.108 | 0.931 (0.775–1.119) | 0.447 |
| 2-3-4 (≥0.8916) | 0.822 (0.712–0.951) | 0.008 | 0.842 (0.728–0.974) | 0.021 | 0.882 (0.763–1.021) | 0.092 |
| **Cardiovascular mortality** | | | | |
| 1st (≤0.8915) | Ref. | | Ref. | | Ref. | |
| 2nd (0.8916–0.1.7881) | 0.874 (0.695–1.100) | 0.252 | 0.823 (0.684–0.991) | 0.040 | 0.856 (0.711–1.030) | 0.100 |
| 3rd (1.7882–3.1088) | 0.892 (0.709–1.122) | 0.328 | 0.864 (0.720–1.037) | 0.116 | 0.890 (0.742–1.068) | 0.211 |
| 4th (>3.1089) | 0.841 (0.667–1.061) | 0.143 | 0.878 (0.730–1.057) | 0.170 | 0.951 (0.790–1.145) | 0.598 |
| 2-3-4 (≥0.8916) | 0.836 (0.722–0.969) | 0.017 | 0.855 (0.737–0.991) | 0.037 | 0.897 (0.774–1.040) | 0.150 |

Model 1: crude model. Model 2: adjusted for cardiovascular risk factors, such as sex, LDL-C, HDL-C, log(Triglyceride), BMI, lipid lowering therapy, blood pressure, diabetes, smoking, CAD, log(hsCRP), eGFR. Model 3: as model 2 further adjusted for age.

https://doi.org/10.1371/journal.pone.0198373.t002
CVD risk by 21% (95% CI 5%-35%) [17]. Moreover, a genome wide association study identified associations between CVD and several loci on genes involved in telomere biology including TERC, TERT, NaF1, OBF1 and RTEL [17].

While the relationship between telomere length and CVD risk is well established there is limited knowledge about the impact of short telomeres on mortality in medium and high risk populations [4]. The few existing studies reported controversial results. In the MERIT-HF study telomere length was not related to all-cause mortality [4]. However, only 13 patients died during follow-up so that this study is probably underpowered [4].

The present results demonstrate 18 and 16% risk reduction in all-cause and CVD mortality, respectively, in patients with the longer telomeres when compared to those with the shortest telomeres. Adjustment for established cardiovascular risk factors attenuated these results. Additional adjustment for age further weakened the association between RTL and mortality and abolished significance. However, using age-corrected RTL data, patients in the 4th quartile compared to those in the 1st quartile, had 42% and 40% risk reduction in all-cause and CVD mortality, respectively. Adjustment for common confounders did not change this result. Consequently, chronological age is a key factor that explains a significant fraction of RTL’s predictive power for mortality. The large, well-characterized study cohort and the long follow-up period confer substantial strength to our findings. Other studies in high-risk populations, such as the Cardiovascular Health Study (CHS) and the Lifestyle Interventions and Independence for Elders (LIFE) study, also demonstrated increased all-cause mortality in subjects with short telomeres [6,16]. However, the effect size ranges from 4–60% in these studies, which is probably explained by differences in study design, measurement of telomere length and different risk profiles of the study cohorts.

Also the change of telomere length in serial measurements seems to be related to mortality. For example, Goglin et al. analyzed RTL at baseline and after 5 years of follow-up in 954 subjects of the prospective Heart and Soul Study [18]. The variation of telomere length during this period was inversely associated with mortality. Every 325 bp increase in telomere change was associated with 36% lower risk of death (HR: 0.64; 95% CI, 0.54–0.76) [18]. In the LURIC study, no serial measurements of RTL were available so that we could not investigate this aspect.

**Mechanistic considerations**

At present, it is not clear whether or not short telomeres contribute directly to CVD. Smoking, hypertension, diabetes mellitus are established CVD risk factors that are associated with reduced telomere length [1]. Therefore, the relationship between RTL and CVD mortality could simply reflect the adverse effects of these factors on vascular structure and function. However, most CVD risk factors induce oxidative stress and inflammation, both of which are known to accelerate telomere shortening. Short telomeres cause genetic instability and can induce cellular senescence and apoptosis. Therefore, a reduced RTL can promote senescence of endothelial cells and thus impair vessel function and repair [1]. In 2,165 American Indians of the Strong Heart Family Study Peng et al. reported an inverse association between telomere length and arterial stiffness [19]. Short telomeres are also related to a faster progression of atherosclerotic plaques [1] and the presence of unstable plaques in patients with acute coronary syndrome [1]. Other aspects, such as telomere uncapping with subsequent p53/p21-induced senescence may also influence vessel function and mortality risk [5].

**Analytical considerations**

In the present study telomere length was assessed in blood leucocytes with a Q-PCR based method. This method determines the average relative telomere length of all chromosomes and
all cells in a sample whereby telomere length is compared to a single copy reference gene. Q-PCR based methods are fast, highly sensitive, sufficiently cost-effective, allow high-throughput and require only small amounts of DNA. Although qPCR is an acceptable method for the assessment of telomere length, Southern blotting is considered the gold standard. Previous studies analyzing the correlation between both methods have reported a curvilinear relationship [20]. The larger measurement error of qPCR versus Southern blot could be a potential source of inconsistency in prior association studies with telomere length [20]. Other methods like quantitative fluorescence in situ hybridization (Q-FISH) and flow-cytometry (flow-FISH) provide additional information about the variability of telomere length between individual cells of the same sample. However, they require vital cells, which limits their application in large-scale epidemiological studies.

Fig 4. Relationship between RTL and all-cause mortality. RTL was modelled as restricted cubic spline in Cox regression analysis and plotted against the log relative hazard with 95% confidence intervals.

https://doi.org/10.1371/journal.pone.0198373.g004
Another important aspect of the present study is the correction of RTL for age. The natural shortening of telomeres with age is modified by factors that accelerate or slow down this process. Consequently, the same RTL in a young and an old person has a different meaning. Age correction has been used in previous studies but there is no consensus on the correct approach [21,22]. For example, age-adjustment has been performed by subtracting the RTL at the 50th age-specific percentile in the study-cohort from the measured RTL of a sample [21]. Others have expressed age-adjusted RTL as z score [22]. In the present study, RTL was divided by age. This method better reflects the continuous decline of RTL with age, considers the characteristics of individual subjects and does not depend from the entire cohort. However, to ensure that age correction did not change the principle outcome of the study, we performed all tests before and after age-correction. Most effects were already visible when crude RTLs were used, but accentuated substantially after age correction.

Conclusions

In conclusion, the present study supports the hypothesis that short telomere length increases the risk of all-cause and CVD mortality. However, a significant fraction of this association is explained by established cardiovascular risk factors, in particular chronologic age. It remains unclear whether short telomeres directly contribute to the increase in mortality or if they are simply a surrogate marker for other adverse processes of aging.

Supporting information

S1 Table. Baseline characteristics according to age-corrected RTL quartiles.

S2 Table. Cox regression for all-cause and CVD-mortality according to age-corrected RTL quartiles.

S1 Fig. Kaplan-Meier plots. Cumulative survival according to age-corrected RTL quartiles (A), age-corrected RTL quartile 1 versus all others quartiles (B).

S2 Fig. Relationship between age-corrected RTL and all-cause mortality. Age-corrected RTL was modelled as restricted cubic spline in Cox regression analysis and plotted against the log relative hazard with 95% confidence intervals.

Author Contributions

Conceptualization: Wolfgang Herrmann, Winfried März, Markus Herrmann.

Data curation: Irene Pusceddu, Marcus Kleber, Graciela Delgado.

Formal analysis: Irene Pusceddu, Marcus Kleber.

Funding acquisition: Wolfgang Herrmann, Winfried März, Markus Herrmann.

Investigation: Irene Pusceddu.

Methodology: Irene Pusceddu, Wolfgang Herrmann, Markus Herrmann.

Project administration: Wolfgang Herrmann, Winfried März, Markus Herrmann.

Resources: Wolfgang Herrmann, Winfried März, Markus Herrmann.
Software: Marcus Kleber.
Supervision: Wolfgang Herrmann, Winfried Márz, Markus Herrmann.
Validation: Irene Pusceddu, Wolfgang Herrmann, Markus Herrmann.
Visualization: Irene Pusceddu, Wolfgang Herrmann, Markus Herrmann.
Writing – original draft: Irene Pusceddu, Graciela Delgado, Wolfgang Herrmann, Winfried Márz.

Writing – review & editing: Marcus Kleber, Graciela Delgado, Wolfgang Herrmann, Winfried Márz.

References

1. Yeh JK, Wang CY. Telomeres and telomerase in cardiovascular diseases. Genes 2016; 7:1–18
2. Willeit P, Willeit J, Brandstatter A, Ehlenbach S, Mayr A, Gasperi A, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2010; 30:1649–56 https://doi.org/10.1161/ATVBAHA.110.205492 PMID: 20508208
3. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369:107–14 https://doi.org/10.1016/S0140-6736(07)60071-3 PMID: 17224733
4. van der Harst P, van der Steeg G, de Boer RA, Voors AA, Hall AS, Mulder MJ, et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 2007; 49:1459–64 https://doi.org/10.1016/j.jacc.2007.01.027 PMID: 17397675
5. Morgan RG, Ives SJ, Walker AE, Cawthon RM, Andtbacka RH, Noyes D, et al. Role of arteriolar telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping. J Hypertens 2014; 32:1293–9 https://doi.org/10.1097/HJH.0000000000000157 PMID: 24686009
6. Fitzpatrick AL, Krommal RA, Kimura M, Gardner JP, Psaty BM, Jenny NS, et al. Leukocyte telomere length and mortality in the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2011; 66:421–9 https://doi.org/10.1093/gerona/glq224 PMID: 21289018
7. Svensson J, Karlsson MK, Ljunggren O, Tivesten A, Mellstrom D, Moverare-Sktic S. Leukocyte telomere length is not associated with mortality in older men. Exp Gerontol 2014; 57:6–12 https://doi.org/10.1016/j.exger.2014.04.013 PMID: 24793325
8. Mons U, Muezzinler A, Schoettker B, Diefenbach AK, Butterbach K, Schick M, et al. Leukocyte telomere length and all-cause mortality, cardiovascular disease, and cancer mortality: results from individual-participant-data meta-analysis of 2 large prospective cohort studies. American Journal of Epidemiology 2017; 1–10
9. Needham BL, Rehkopf D, Adler N, Gregorich S, Lin J, Blackburn EH, et al. Leukocyte telomere length and mortality in the National Health and Nutrition Examination Survey, 1999–2002. Epidemiol, 2015; 26:526–35 https://doi.org/10.1097/EDE.0000000000000296 PMID: 26039272
10. Rode L, Nordestgaard BG, Bojesen SE. Peripheral blood leukocyte telomere length and mortality among 64637 individuals from the general population. J Natl Cancer Inst 2015; 107:1–8
11. Winkelmann BR, Maerz W, Boehm BO, Zott R, Hager J, Hellstern P, Seneges J. Rationale and design of the LURIC study: A supplement of pharmacogenomics 2001; 2:1–73
12. Pusceddu I, Herrmann M, Kirsch SH, Werner C, Huebner U, Bodis M, et al. Prospective study of telomere length and LINE-1 methylation in peripheral blood cells: the role of B vitamins supplementation. Eur J Nutr 2016; 55:1663–73 https://doi.org/10.1007/s00394-015-1003-1 PMID: 26293976
13. Dean GS, Zhang C, Gao J, Roy S, Shinkle J, Sabarinathan M, et al. The association between telomere length and mortality in Bangladesh. Aging 2017; 9:1537–1551 https://doi.org/10.18632/aging.101246 PMID: 28630379
14. Madrid AS, Rode L, Nordestgaard BG, Bojesen SE. Short telomere length and ischemic heart disease: observational and genetic studies in 290022 individuals. Clinical Chemistry 2016; 62:1140–9 https://doi.org/10.1373/clinchem.2016.258566 PMID: 27259814
16. Fyhrquist F, Silventoinen K, Saijonmaa O, Kontula K, Devereux RB, de Faire U, et al. Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens. 2011; 25:711–8 https://doi.org/10.1038/jhh.2011.57 PMID: 21697896

17. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013; 45:422–7 https://doi.org/10.1038/ng.2528 PMID: 23535734

18. Goglin SE, Farzaneh-Far R, Epel ES, Lin J, Blackburn EH, Whooley MA. Change in leukocyte telomere length predicts mortality in patients with stable coronary heart disease from the Heart and Soul Study. PloSOne 2016; 1–12

19. Peng H, Zhu Y, Yeh F, Cole SA, Best LG, Lin J, et al. Impact of biological aging on arterial aging in American Indians: findings from the Strong Heart Family Study. Aging 2016; 8:1583–91 https://doi.org/10.18632/aging.101013 PMID: 27540694

20. Elbers CC, Garcia EM, Kimura M, Cummings SR, Nalls MA, Newman AB, et al. Comparison between Southern Blots and qPCR analysis of leukocyte telomere length in the Health ABC study. J Gerontol A Biol Sci Med Sci 2014; 69:527–531 https://doi.org/10.1093/gerona/glt121 PMID: 23946336

21. Barbaro PM, Mateos M, Dalla-Pozza L, et al. Age adjusted telomere length decreases following treatment for pediatric acute lymphoblastic leukemia, but does not predict toxicity. Blood 2015; 126:4984

22. Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdrop PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 2012; 97:353–9 https://doi.org/10.3324/haematol.2011.055269 PMID: 22058220